Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Design Therapeutics (DSGN) Cash from Financing Activities (2020 - 2026)

Design Therapeutics' Cash from Financing Activities history spans 2 years, with the latest figure at $193000.0 for Q4 2021.

  • On a quarterly basis, Cash from Financing Activities rose 19200.0% to $193000.0 in Q4 2021 year-over-year; TTM through Dec 2021 was $379.2 million, a 751.55% increase, with the full-year FY2025 number at $25.7 million, up 4917.15% from a year prior.
  • Cash from Financing Activities hit $193000.0 in Q4 2021 for Design Therapeutics, up from $30000.0 in the prior quarter.
  • Over the last five years, Cash from Financing Activities for DSGN hit a ceiling of $379.0 million in Q1 2021 and a floor of $1000.0 in Q4 2020.